- home
- Advanced Search
Filters
Clear All- COVID-19
- Publications
- Other research products
- French National Research Agency (AN...
- IDMIT
- Nature
- COVID-19
- Publications
- Other research products
- French National Research Agency (AN...
- IDMIT
- Nature
Loading
description Publicationkeyboard_double_arrow_right Article 2020 FrancePublisher:Springer Science and Business Media LLC Funded by:EC | EVAg, EC | TRANSVAC2, ANR | IDMIT +3 projectsEC| EVAg ,EC| TRANSVAC2 ,ANR| IDMIT ,EC| CARE ,EC| Fight-nCoV ,EC| EVA-GLOBALPauline Maisonnasse; Jeremie Guedj; Vanessa Contreras; Sylvie Behillil; Caroline Solas; Romain Marlin; Thibaut Naninck; Andrés Pizzorno; Julien Lemaitre; Antonio Gonçalves; Nidhal Kahlaoui; Olivier Terrier; Raphael Ho Tsong Fang; Vincent Enouf; Nathalie Dereuddre-Bosquet; Angela Brisebarre; Franck Touret; Catherine Chapon; Bruno Hoen; Bruno Lina; Manuel Rosa Calatrava; Sylvie van der Werf; Xavier de Lamballerie; Roger Le Grand;pmid: 32698191
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-194-7. Here we evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (Vero E6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to a placebo treatment, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor the combination of HCQ and AZTH showed a significant effect on viral load in any of the analysed tissues. When the drug was used as a pre-exposure prophylaxis treatment, HCQ did not confer protection against infection with SARS-CoV-2. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans. International audience
HAL-Pasteur; HAL-ENS... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s41586-020-2558-4&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 286 citations 286 popularity Top 0.1% influence Top 1% impulse Top 0.1% Powered by BIP!more_vert HAL-Pasteur; HAL-ENS... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s41586-020-2558-4&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu
Loading
description Publicationkeyboard_double_arrow_right Article 2020 FrancePublisher:Springer Science and Business Media LLC Funded by:EC | EVAg, EC | TRANSVAC2, ANR | IDMIT +3 projectsEC| EVAg ,EC| TRANSVAC2 ,ANR| IDMIT ,EC| CARE ,EC| Fight-nCoV ,EC| EVA-GLOBALPauline Maisonnasse; Jeremie Guedj; Vanessa Contreras; Sylvie Behillil; Caroline Solas; Romain Marlin; Thibaut Naninck; Andrés Pizzorno; Julien Lemaitre; Antonio Gonçalves; Nidhal Kahlaoui; Olivier Terrier; Raphael Ho Tsong Fang; Vincent Enouf; Nathalie Dereuddre-Bosquet; Angela Brisebarre; Franck Touret; Catherine Chapon; Bruno Hoen; Bruno Lina; Manuel Rosa Calatrava; Sylvie van der Werf; Xavier de Lamballerie; Roger Le Grand;pmid: 32698191
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-194-7. Here we evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (Vero E6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to a placebo treatment, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor the combination of HCQ and AZTH showed a significant effect on viral load in any of the analysed tissues. When the drug was used as a pre-exposure prophylaxis treatment, HCQ did not confer protection against infection with SARS-CoV-2. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans. International audience
HAL-Pasteur; HAL-ENS... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s41586-020-2558-4&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 286 citations 286 popularity Top 0.1% influence Top 1% impulse Top 0.1% Powered by BIP!more_vert HAL-Pasteur; HAL-ENS... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1038/s41586-020-2558-4&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu